Cargando…
Patients with geographic barriers to health care access are prescribed a higher proportion of drugs with pharmacogenetic testing guidelines
Pharmacogenetic (PGx) testing may be particularly beneficial in medically underserved populations by reducing the number of appointments required to optimize drug therapy and increasing the effectiveness of less expensive off‐patent drugs. The objective of this study was to identify patient populati...
Autores principales: | Dalton, Rachel, Brown, Joshua D., Duarte, Julio D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504817/ https://www.ncbi.nlm.nih.gov/pubmed/33955180 http://dx.doi.org/10.1111/cts.13032 |
Ejemplares similares
-
What Are the Barriers and Enablers to the Implementation of Pharmacogenetic Testing in Mental Health Care Settings?
por: Jameson, Adam, et al.
Publicado: (2021) -
Patients’ Perspectives of Factors That Influence Pharmacogenetic Testing Uptake: Enhancing Patient Counseling and Results Dissemination
por: Bagautdinova, Diliara, et al.
Publicado: (2022) -
Pharmacogenetic actionability and medication prescribing in people with cystic fibrosis
por: Anderson, Justin D., et al.
Publicado: (2023) -
Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines: A Systematic Review
por: Morris, Sarah A., et al.
Publicado: (2022) -
Exploring perceptions, knowledge, and attitudes regarding pharmacogenetic testing in the medically underserved
por: Gawronski, Brian E., et al.
Publicado: (2023)